We use cookies on our site to analyze traffic, enhance your experience, and provide you with tailored content.

For more information visit our privacy policy.

Licensed Antibodies Sample Clauses

Licensed Antibodies. Subject to (i) MorphoSys’ and/or its Affiliates’ existing (as of the Effective Date) HuCAL agreements, comprising any obligation for MorphoSys and/or its Affiliate(s) to generate or have generated antibodies to which MorphoSys’ and/or its Affiliates’ contract partners have any rights whatsoever, and (ii) any non-therapeutic, non-prophylactic activity of MorphoSys and/or its Affiliate(s), MorphoSys hereby covenants that, during the Term, MorphoSys and its Affiliates shall not preclinically develop, develop in any human clinical trial, seek Market Authorization for, or in any way commercialize in the MorphoSys Territory any […***…] other than any Licensed Antibody and/or Licensed Products that are payment-bearing to Xencor under this Agreement (other than a Licensed Product for which the Royalty Term has expired, after such expiration; this covenant does not apply at such times to such Licensed Product). Sublicensees specifically do not make such covenant, and MorphoSys does not make such covenant as to Sublicensees.
Sample 1Sample 2Sample 3See All (6)
Licensed Antibodies. The term "Licensed Antibodies" shall mean the antibodies set forth in Exhibit A hereto, and any subsequent monoclonal antibodies owned, licensed or developed by M-Tech or its Affiliates that are directed towards the same antigens as the antibodies listed in Exhibit A. Expressly excluded from the Licensed Antibodies are any subclone cell lines isolated from the [***] cell line other than those that primarily produce human monoclonal antibodies to [***], whether alone or in combination with other antigens.
Sample 1Sample 2
Licensed Antibodies. (i) Subject to the terms and conditions of this Agreement, Kadmon hereby grants to Jinghua an exclusive license, with the right to grant sublicenses in accordance with Section 3.2, under the Intellectual Property Controlled by Kadmon as of the Effective Date, including the Kadmon Patents, to use, have used, Develop, have Developed, Manufacture, have Manufactured, Commercialize and have Commercialized Products in the Territory. For the avoidance of doubt, to the extent a Third Party contributed to the Licensed Antibody, no such license shall be granted to the extent (1) Kadmon does not have the right to do so under its contractual relationship with such Third Party, or (2) if doing so causes Kadmon to incur any payment obligation to any Third Party. (ii) Further, subject to the terms and conditions of this Agreement, Kadmon hereby grants to Jinghua an exclusive license, with the right to grant sublicenses in accordance with Section 3.2 all Know-How arising from the research, discovery and development activities related to the Licensed Antibodies undertaken by or on behalf of Kadmon during the term of this Agreement, which Know-How is incorporated into any Product or useful for the making of a Product. (iii) Kadmon shall assign to Jinghua all Patents in the Territory arising from the research, discovery and development activities relating to the Licensed Antibodies undertaken by or on behalf of Kadmon during the term of this Agreement (the “Kadmon Assigned Patents”), using the form of patent assignment attached hereto as Exhibit C.
Sample 1Sample 2
Licensed Antibodies. Licensor has disclosed to EQRx all Antibodies that Licensor or any of its Affiliates owns or in-licenses, as of the Execution Date, that relate to the Licensed Antibodies.
Sample 1
Licensed Antibodies. With respect to each Licensed Antibody isolated by Licensee under the Library License granted to Licensee under Section 3.1(a) above, and subject to the terms and conditions of this Agreement (including without limitation, the restrictions set forth in Sections 3.2, 3.3, 3.4, 3.5, 3.6 and 3.7 and the payment obligations set forth in Article 4), Dyax hereby grants to Licensee and its Affiliates:  (i) a world-wide, non-exclusive, royalty-free license, under the Dyax Technology, Affimed Patent Rights, Biosite Patent Rights, CAT Patent Rights, Domantis Patent Rights and Genentech Patent Rights to use, have used, develop, make, have made, and import Licensed Antibodies, solely in the Research Field (the "Research License"); and (ii) an option to obtain a worldwide, non-exclusive license, under the Dyax Technology, Affimed Patent Rights, Biosite Patent Rights, CAT Patent Rights, Domantis Patent Rights and Genentech Patent Rights to develop, make, have made, use, have used, sell, offer for sale, have sold, import and export Therapeutic Antibody Products to the applicable Target in the Commercial Field (the "Commercial License") on the following terms:  (A) Licensee shall have no rights to obtain a Commercial License unless Licensee also obtains a sublicense to a CAT Product License with respect to the applicable Target as contemplated in Section 3.4(b)(iv) hereof; (B) once Licensee has obtained a sublicense to a CAT Product License to the applicable Licensee Target (which must be obtained prior to the commencement of the first Phase I Clinical Trial of a Therapeutic Antibody Product or two (2) years following the expiration of the Library license Term), Dyax shall and hereby does grant to Licensee a Commercial License to the applicable Target (which Commercial License shall not be evidenced by a separate agreement but shall be automatically granted upon execution of a CAT Sublicense with respect to the applicable licensee Target);  (C) the Commercial License granted to Licensee under Section 3.1(b)(ii) shall be subject to the terms and conditions of this Agreement, including without limitation, the restrictions set forth in Sections 3.2, 3.3, 3.4, 3.5, 3.6 and 3.7 and the payment obligations set forth in Article 4;  (D) subject to the restrictions imposed by the CAT and XOMA Agreements (as set forth in Sections 3.4 and 3.7), licensee may sublicense the rights granted to Licensee under the Commercial License to allow Third Parties to use Licensed Antibodies an...
Sample 1

Related to Licensed Antibodies

  • Commercialization Intrexon shall have the right to develop and Commercialize the Reverted Products itself or with one or more Third Parties, and shall have the right, without obligation to Fibrocell, to take any such actions in connection with such activities as Intrexon (or its designee), at its discretion, deems appropriate.

  • Research Collaboration 3.7.1 Aarvik shall carry out the activities of each Work Item and deliver the required Data Package and/or deliverables in accordance with the applicable SOW. Without limiting the generality of the foregoing, Aarvik shall, in accordance with the applicable SOWs and the timeline approved by JRC, apply the Aarvik IP to (i) design and synthesize Collaboration Compounds, and (ii) by itself or through subcontractor(s), [***]. During the Research Term, if any Party identifies any Third Party Patent or Know-How that is necessary or reasonably useful for any activity under the SOWs but has not been included in the Aarvik IP, then such Party shall immediately inform the other Party and the Parties shall discuss in good faith the need of obtaining a license from such Third Party. 3.7.2 No later than [***] ([***]) days after completion of the [***], Aarvik shall, to the extent not already provided to ArriVent, deliver the Data Packages and all other deliverables required under the [***], as well as the results of the Patentability and FTO Analysis as described in Section 3.2.3, to ArriVent. ArriVent shall have the sole discretion to decide whether or not to advance any Collaboration Compound and which Collaboration Compound(s) will be advanced for further studies beyond the [***]. ArriVent shall inform Axxxxx of its decision in writing. If AxxxXxxx decides to advance the Collaboration Program to [***], ArriVent shall make the payment for the [***] pursuant to Section 6.2.1. 3.7.3 If, upon completion of the [***] for the Collaboration Program, AxxxXxxx decides not to advance the Collaboration Program to [***], ArriVent may terminate the Collaboration Program. If AxxxXxxx decides to advance the Collaboration Program to [***], ArriVent shall make the payment for the [***] pursuant to Section 6.2.1. 3.7.4 No later than [***] ([***]) days after completion of the [***], Aarvik shall, to the extent not already provided to ArriVent, deliver all Data Packages and deliverables required under the [***] to ArriVent. ArriVent shall have the sole discretion to decide whether or not to advance any Collaboration Compound and which Collaboration Compound(s) will be advanced for further studies beyond the [***]. ArriVent shall inform Axxxxx of its decision in writing. 3.7.5 No later than [***] ([***]) days after completion of the [***], Aarvik shall, to the extent not already provided to ArriVent, deliver all Data Packages and deliverables required under the [***] to ArriVent. 3.7.6 Within [***] ([***]) days after completion of the [***], Aarvik shall deliver to ArriVent a full report on all key results and findings of the Collaboration Program, and such other data, results and information as ArriVent may deem necessary for it to determine whether or not to exercise the Option (the “Full Report”).

  • Development and Commercialization Subject to Sections 4.6 and 4.7, Fibrocell shall be solely responsible for the development and Commercialization of Fibrocell Products and Improved Products. Fibrocell shall be responsible for all costs incurred in connection with the Fibroblast Program except that Intrexon shall be responsible for the following: (a) costs of establishing manufacturing capabilities and facilities in connection with Intrexon’s manufacturing obligation under Section 4.6 (provided, however, that Intrexon may include an allocable portion of such costs, through depreciation and amortization, when calculating the Fully Loaded Cost of manufacturing a Fibrocell Product, to the extent such allocation, depreciation, and amortization is permitted by US GAAP, it being recognized that the majority of non-facilities scale-up costs cannot be capitalized and amortized under US GAAP); (b) costs of basic research with respect to the Intrexon Channel Technology and Intrexon Materials (i.e., platform improvements) but, for clarity, excluding research described in Section 4.7 or research requested by the JSC for the development of a Fibrocell Product or an Improved Product (which research costs shall be reimbursed by Fibrocell); (c) [*****]; and (d) costs of filing, prosecution and maintenance of Intrexon Patents. The costs encompassed within subsection (a) above shall include the scale-up of Intrexon Materials and related active pharmaceutical ingredients for clinical trials and Commercialization of Fibrocell Products undertaken pursuant to Section 4.6, which shall be at Intrexon’s cost whether it elects to conduct such efforts internally or through Third Party contractors retained by either Intrexon or Fibrocell (with Intrexon’s consent).

Most Referenced Clauses

Most Referenced Definitions